Journal article
The Effects of Modafinil Treatment on Neuropsychological and Attentional Bias Performance During 7-Day Inpatient Withdrawal From Methamphetamine Dependence
R Hester, N Lee, A Pennay, S Nielsen, J Ferris
Experimental and Clinical Psychopharmacology | AMER PSYCHOLOGICAL ASSOC | Published : 2010
DOI: 10.1037/a0021791
Abstract
The cognitive benefits of modafinil to patients undergoing 7-day inpatient withdrawal from methamphetamine (MA) dependence were examined as part of a double-blind, randomized, placebo-controlled pilot trial. Recent evidence has identified modafinil-related improvements in treatment outcomes for MA-dependent patients; however, the benefits to cognition function, which is critical to treatment success but known to be impaired, has yet to be examined. The first 20 participants recruited to the study were administered either 200 mg of modafinil (once daily) or placebo, and a neuropsychological test battery (including an MA version of the emotional Stroop task) at admission (n = 17) and discharge..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This research was supported by the Illicit Drugs Section, Drugs Strategy Branch, Australian Government Department of Health and Ageing and National Health and Medical Research Council Fellowship (519730) (to R.H.). The Department of Health and Ageing had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. R.H. developed the cognitive tasks and neuropsychological battery, analyzed and interpreted the data, and wrote the article. N.L. developed the measures and design for the entire randomized clinical trial, A.P. recruited participants and administered the cognitive tests. J.F. provided statistical advice. S.N. dispensed the trial medication. All authors contributed to the drafts of the article. All authors declare that they have no conflicts of interest. The assistance of clinical staff at both sites are gratefully acknowledged. Our trial is registered with the Australian New Zealand Clinical Trials Registry - number is AC-TRN12606000272594.